BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

993 related articles for article (PubMed ID: 31319389)

  • 1. Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
    Ajani JA; D'Amico TA; Bentrem DJ; Chao J; Corvera C; Das P; Denlinger CS; Enzinger PC; Fanta P; Farjah F; Gerdes H; Gibson M; Glasgow RE; Hayman JA; Hochwald S; Hofstetter WL; Ilson DH; Jaroszewski D; Johung KL; Keswani RN; Kleinberg LR; Leong S; Ly QP; Matkowskyj KA; McNamara M; Mulcahy MF; Paluri RK; Park H; Perry KA; Pimiento J; Poultsides GA; Roses R; Strong VE; Wiesner G; Willett CG; Wright CD; McMillian NR; Pluchino LA
    J Natl Compr Canc Netw; 2019 Jul; 17(7):855-883. PubMed ID: 31319389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esophageal and esophagogastric junction cancers, version 1.2015.
    Ajani JA; D'Amico TA; Almhanna K; Bentrem DJ; Besh S; Chao J; Das P; Denlinger C; Fanta P; Fuchs CS; Gerdes H; Glasgow RE; Hayman JA; Hochwald S; Hofstetter WL; Ilson DH; Jaroszewski D; Jasperson K; Keswani RN; Kleinberg LR; Korn WM; Leong S; Lockhart AC; Mulcahy MF; Orringer MB; Posey JA; Poultsides GA; Sasson AR; Scott WJ; Strong VE; Varghese TK; Washington MK; Willett CG; Wright CD; Zelman D; McMillian N; Sundar H;
    J Natl Compr Canc Netw; 2015 Feb; 13(2):194-227. PubMed ID: 25691612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
    Ajani JA; D'Amico TA; Bentrem DJ; Cooke D; Corvera C; Das P; Enzinger PC; Enzler T; Farjah F; Gerdes H; Gibson M; Grierson P; Hofstetter WL; Ilson DH; Jalal S; Keswani RN; Kim S; Kleinberg LR; Klempner S; Lacy J; Licciardi F; Ly QP; Matkowskyj KA; McNamara M; Miller A; Mukherjee S; Mulcahy MF; Outlaw D; Perry KA; Pimiento J; Poultsides GA; Reznik S; Roses RE; Strong VE; Su S; Wang HL; Wiesner G; Willett CG; Yakoub D; Yoon H; McMillian NR; Pluchino LA
    J Natl Compr Canc Netw; 2023 Apr; 21(4):393-422. PubMed ID: 37015332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant (postoperative) therapy for esophageal cancer.
    Ku GY; Ilson DH
    Thorac Surg Clin; 2013 Nov; 23(4):525-33. PubMed ID: 24199702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controversies in the treatment of local and locally advanced gastric and esophageal cancers.
    Cohen DJ; Leichman L
    J Clin Oncol; 2015 Jun; 33(16):1754-9. PubMed ID: 25918302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adenocarcinoma of the esophagogastric junction.
    Jenkins TD; Friedman LS
    Dig Dis; 1999; 17(3):153-62. PubMed ID: 10697664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unanswered questions in the management of gastroesophageal junction adenocarcinoma: an overview from the medical oncologist's perspective.
    Shah MA
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study with cetuximab and radiation therapy for patients with surgically resectable esophageal and GE junction carcinomas: Hoosier Oncology Group G05-92.
    Becerra CR; Hanna N; McCollum AD; Becharm N; Timmerman RD; DiMaio M; Kesler KA; Yu M; Yan T; Choy H
    J Thorac Oncol; 2013 Nov; 8(11):1425-9. PubMed ID: 24084441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative and adjuvant therapies for upper gastrointestinal cancers.
    Varadhachary G; Ajani JA
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):719-25. PubMed ID: 16111471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment approaches to esophagogastric junction tumors.
    Kurokawa Y; Sasako M; Doki Y
    Dig Surg; 2013; 30(2):169-73. PubMed ID: 23867594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemoradiation for locally advanced resectable carcinoma of the esophagus: A single-center experience from India with a brief review of the literature.
    Krishnamurthy A; Mohanraj N; Radhakrishnan V; John A; Selvaluxmy G
    Indian J Cancer; 2017; 54(4):646-651. PubMed ID: 30082551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endoscopic Submucosal Dissection for Adenocarcinomas of the Esophagogastric Junction.
    Nagami Y; Ominami M; Otani K; Hosomi S; Tanaka F; Taira K; Kamata N; Yamagami H; Tanigawa T; Shiba M; Watanabe T; Fujiwara Y
    Digestion; 2018; 97(1):38-44. PubMed ID: 29393168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of esophagogastric junction carcinoma: an unsolved debate.
    Orditura M; Galizia G; Lieto E; De Vita F; Ciardiello F
    World J Gastroenterol; 2015 Apr; 21(15):4427-31. PubMed ID: 25914451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus.
    Moehler M; Baltin CT; Ebert M; Fischbach W; Gockel I; Grenacher L; Hölscher AH; Lordick F; Malfertheiner P; Messmann H; Meyer HJ; Palmqvist A; Röcken C; Schuhmacher C; Stahl M; Stuschke M; Vieth M; Wittekind C; Wagner D; Mönig SP
    Gastric Cancer; 2015 Jul; 18(3):550-63. PubMed ID: 25192931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distant Oncologic Outcome of Patients with Locally Advanced Unresectable and Metastatic Esophageal Cancer after Multimodality Treatment.
    Anghel R; Constantinoiu S; Bacinschi X; Gales L; Toma RV; Trifanescu O
    Chirurgia (Bucur); 2018; 113(1):116-122. PubMed ID: 29509538
    [No Abstract]   [Full Text] [Related]  

  • 16. Esophageal Cancer: New Insights into a Heterogenous Disease.
    Krug S; Michl P
    Digestion; 2017; 95(4):253-261. PubMed ID: 28384630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esophagogastric junction and gastric adenocarcinoma: neoadjuvant and adjuvant therapy, and future directions.
    Sandler S
    Oncology (Williston Park); 2014 Jun; 28(6):505-12. PubMed ID: 25134325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer of the gastroesophageal junction: combined modality therapy.
    Ilson DH
    Surg Oncol Clin N Am; 2006 Oct; 15(4):803-24. PubMed ID: 17030275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of short-term effectiveness of eight targeted agents combined with chemotherapy for treating esophageal-gastric junction adenocarcinoma: A network meta-analysis.
    He YM; Yu C; Li WB; Li ZP; Xu N
    J Cell Biochem; 2018 Jan; 119(1):1183-1192. PubMed ID: 28708307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of preoperative concurrent chemoradiotherapy with chemotherapy alone in patients with locally advanced siewert II and III adenocarcinoma of the esophagogastric junction.
    Ge X; Zhao Q; Song Y; Li J; Liu M; Bai W; Qiao X
    Eur J Surg Oncol; 2018 Apr; 44(4):502-508. PubMed ID: 29395438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.